Responses
Regular Abstracts – Part 2
Biomarkers, Immune Monitoring and Novel Technologies
222-N Analysis of pathologic features and efficacy outcomes with neoadjuvant nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer in CheckMate 816
Compose a Response to This Article
Other responses
No responses have been published for this article.
